The ICCS 2020 showcases 20 emerging oncology companies advancing an exciting portfolio of novel therapeutic, diagnostic, and digital solutions to fight cancer. This event features four thematic sessions with five companies each highlighting their technologies and partnering opportunities.

**Session 1: Targeting Novel Mechanisms**
Welcome from the ICCS 2020 Organizing Partners.
- SideROS
- Adecto
- Ecrins Therapeutics
- AC BioScience
- EXACT Therapeutics

**Session 2: I-O and Cell Therapy**
Takeda Presentation, Alexandra Huhalov, Search & Evaluation Lead, Oncology, Center for External Innovation, Takeda Pharmaceuticals.
- Nextera
- Apmonia Therapeutics
- Elthera
- CytoSeek
- IO Biosciences

**Session 3: I-O, Oncolytic Viruses and Vaccines**
“Future Tech Industries” by DNB
- PsiVac
- ImmunoGenesis
- Oxford Vacmedix
- Geneos Therapeutics
- B Cell Design

**Session 4: Diagnostics and Digital Health Interventions**
"Monitoring in the COVID Environment" by Francisco Vega, VP Global Clinical Monitoring, Precision for Medicine.
- Naveris
- Asylia Diagnostics
- Adiposs
- Kaiku Health
- ODS Medical

**Contact information:**

**MASSACHUSETTS:** Abigail Barrow, abarrow@cambridgeinno.com, Christa Bleyleben, cbleyleben@massglobalpartners.com  
**QUÉBEC:** Nathalie Ouimet, nouimet@montreal-invivo.com  
**PHILADELPHIA:** Heather A. Steinman, hsteinman@wistar.org  
**NORWAY:** Jutta Heix, jh@oslocancercluster.no  
**UK:** John Harris, John.Harris@obn.org.uk  
**SWITZERLAND:** Olivier Philippe, olivier.philippe@biopole.ch  
**MATWIN:** Lucia Robert, lucia.robert@matwin.fr

For more information, please visit: [internationalcancercluster.org](http://internationalcancercluster.org)
**Session 1: Targeting Novel Mechanisms**

Welcome from the ICCS 2020 Organizing Partners.

---

**SideROS** is a French biotech company bridging innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to relapse and metastasis.

**Contact:** Lucie Mondoulet, CEO  
Tel.: +33 6 62 59 0417, E-mail: lucie.mondoulet@sideros.bio

---

**Adecto Pharmaceuticals** is developing a targeted antibody therapy and companion diagnostic for patients with ADAM8-driven breast, colon and stomach cancers. Leads for both products are advancing through preclinical development to IND enabling studies and CLIA validation.

**Contact:** Nora Mineva, Ph.D., Chief Scientific Officer  
Tel.: +1 617 645 2931, E-mail: nora.mineva@adectopharma.com

---

**Ecrins Therapeutics** is a French privately-owned biotech company developing breakthrough drugs for the therapy of cancer and rare diseases. Our lead product ET-D5 is at the door of the first-in-human clinical trial for the treatment of bone and soft-tissue sarcomas.

**Contact:** Andrei Popov, CEO  
Tel.: +33 4 76 54 9566, E-mail: andrei.popov@ecrins-therapeutics.com

---

**AC BioScience** (based at Biopôle) is a Swiss biotech company with two of its three drug candidates about to enter clinical trials. The lead compound ACB1801 reverts the tumor phenotype in order to improve MHC-1 mediated antigens presentation, and thereby potentiates the efficacy of anti PD-1 therapy.

**Contact:** Andreas Schlaepfer, CEO & Co-founder  
Tel.: +41 79 308 9929, E-mail: andreas.schlaepfer@ac-bioscience.com

---

**EXACT** is a clinical stage Norwegian biotech company developing a technology platform for ultrasound-mediated, targeted therapeutic enhancement. Acoustic Cluster Therapy (ACT®) is capable of significantly amplifying the clinical utility of a wide range of therapeutic agents across a multitude of indications.

**Contact:** Dr. Rafiq Hasan, CEO Designate  
E-mail: rafiq@exact-tx.com

---

**EXACT: Therapeutics** is a clinical stage Norwegian biotech company developing a technology platform for ultrasound-mediated, targeted therapeutic enhancement. Acoustic Cluster Therapy (ACT®) is capable of significantly amplifying the clinical utility of a wide range of therapeutic agents across a multitude of indications.

**Contact:** Dr. Rafiq Hasan, CEO Designate  
E-mail: rafiq@exact-tx.com
Session 2: I-O and Cell Therapy

Takeda Presentation, Alexandra Huhalov, Search & Evaluation Lead, Oncology, Center for External Innovation, Takeda Pharmaceuticals.

**Nextera**’s aim is to modulate disease at the core of T cell immunity to obtain disease-specific treatment. Our unique drug and target discovery engine, NextCore, fosters both the development of T cell receptor (TCR) drugs and target reactivity profiling in Immuno-oncology.

**Contact:** Geir Åge Løset, CEO  
Tel.: +47 45025241, E-mail: galoset@nextera.no

**Apmonia Therapeutics** is a French biotech company developing immunotherapies for the treatment of solid tumors. Our peptide-based approach reprograms the tumor microenvironment through selective antagonization of TSP-1/CD47 signaling.

**Contact:** Dr. Albin Jeanne, CEO  
Tel.: +33 6 31 41 3068, E-mail: a.jeanne@apmonia-therapeutics.com

**Elthera**, a Swiss biotech company, is developing a T cell engaging bispecific antibody against the novel target LICAM™ for the treatment of solid tumors. The lead compound demonstrated excellent efficacy and will enter preclinical development by end 2020.

**Contact:** Anne Schmidt, CEO  
Tel.: +41 79 771 2535, E-mail: anne.schmidt@elthera.com

**CytoSeek** is a discovery-stage company developing the next generation of cell therapies to treat cancer using its pioneering cell-membrane augmentation technology (Artificial Membrane Binding Proteins or AMBP). AMBP technology enables the addition of new functionalities to cell therapies.

**Contact:** Carolyn Porter, CEO  
Tel.: +44 7795 028465, E-mail: carolyn@cytoseek.uk

**IO Biosciences** is a company focused on developing allogeneic, gene modified cell therapies treating cancers. The company leverages a proprietary gene editing system and cell source, creating a unique opportunity to develop and manufacture off-the-shelf gene modified cell therapies.

**Contact:** Sicco H. Popma, President & CEO  
Tel.: +1 484-680-9357, E-mail: spopma@iobiosciences.com
Session 3: I-O, Oncolytic Viruses and Vaccines

“Future Tech Industries” by DNB

Psivac's unique offering is a safe and powerful oncolytic adenovirus, Ixovex 1 that is highly selective and replicates and self-amplifies in tumour cells. This leads to a significant reduction in toxicity to normal cells, which is a significant advantage in immuno-compromised patients.

Contact: Ghassan Alusi, CEO
Tel.: +44 7964 621037, E-mail: g.alusi@ixogen.com

ImmunoGenesis is driving the next evolution in Immuno-Oncology by developing therapies that catalyze immune responses in immunologically "cold" tumors, which represent more than half of all cancers. The lead therapy, IMGS-001, is a bispecific PD-L1/PD-L2 inhibitor which provides a stronger foundation of PD-1 blockade and the potential for superior efficacy in "hot" and "cold" tumors – Phase IA/IB trial expected to start 1H 2021.

Contact: James Barlow, CEO & President
Tel.: +1 412-841-5570, E-mail: james.barlow@immunogenesis.com

Oxford Vacmedix (OVM) is a spinout from Oxford University exploiting Shisong Jiang’s novel patented technology in the design and development of vaccines. This platform technology is based on the improvements in vaccines associated with the presentation of peptide vaccines as short peptides.

Contact: William Finch, CEO
Tel.: +44 7769 903711, E-mail: wfinch@oxfordvacmedix.com

Geneos leverages DNA immunotherapy technology to identify, design, manufacture, and deliver tumor specific neoantigen-targeted (TSNA-targeted) personalized immunotherapies.

Contact: Niranjan Y. Sardesai, Co-Founder, President & CEO
Tel.: +1 267-440-4232, E-mail: sardesai@geneostx.com

B cell design is a French biotech promoting new therapeutical and diagnostic approaches of mucosal immunotherapies for cancer, inflammation disorders and infectious diseases. We are currently developing a therapeutic IgA antibody candidate with full validated preclinical POC for a brand new drug candidate against cancer (colorectal).

Contact: Armelle Cuvillier, President, CSO
Tel.: +33 630 687 537, E-mail: armelle.cuvillier@b-cell-design.com
Session 4: Diagnostics and Digital Health Interventions

"Monitoring in the COVID Environment" by Francisco Vega, VP Global Clinical Monitoring, Precision for Medicine.

Naveris, Inc. is developing and commercializing novel blood tests to enhance the early detection and clinical management of viral-associated cancers. The company has recently launched the NavDx® test, which uses proprietary technology to detect tumor tissue modified HPV.

Contact: Piyush Gupta, Ph.D., CEO  
Tel.: +1-833-628-3747, E-mail: pgupta@naveris.com

Asylia Diagnostics is developing molecular diagnostics tests to predict hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors. HPD leads to the rapid mortality of patients and is an unmet clinical need. Asylia’s AI-powered intelligent platform and knowledge base for discovery and development of molecular biomarkers allows predicting safety risks for all solid tumors targeted by immunotherapy.

Contact: Andrey Khmelevskiy, CEO  
Tel.: +31 6 27 48 37 36, E-mail: andrey.khmelevskiy@asyliadx.com

Adiposs is a Swiss biotech company developing ImageBAT, a new CT contrast agent for early detection of cachexia, a fatal body wasting condition. The diagnostic scan with ImageBAT will be fast, pain-free and available in every hospital worldwide.

Contact: Andrej Babic, CEO  
Tel.: +41 76 616 1624, E-mail: andrej.babic@adiposs.com

Kaiku Health, personalised digital health interventions for every cancer patient powered by intelligent algorithms and machine learning enabling proactive and predictive cancer care.

Contact: Lauri Sippola, CEO  
Tel.: +358 40744 7481, E-mail: lauri.sippola@kaikuhealth.com

ODS Medical is a medical technology company that brings together the power of molecular imaging and machine learning to develop optical biopsy tools based on Raman spectroscopy. We enable real-time tissue characterization directly in the patient, ushering in a new era of data-driven surgical oncology to operating rooms everywhere.

Contact: Christopher Kent, President & CEO  
Tel.: +1 514 884 0356, E-mail: chriskent@odsmed.com

A Special Thank You to Our Sponsors

Organizers: